

April 25, 2013

Reverse Split

CUSIP#:

Commerzbank AG DR CUSIP: 202597308 DR ISIN: US2025973080 DR Ticker Symbol: CRZBY

Ratio (DRs:Underlying Shares): 1:1

BNY Mellon has been advised that Commerzbank AG announced the implementation of a reverse split of one (1) new share for every ten (10) ordinary shares held in the local market.

As a result BNY Mellon will effect a 1 for 10 reverse stock split on the DR program. Effective April 25, 2013, DR holders of Commerzbank are required on a mandatory basis to surrender their DRS for cancellation and exchange ten (10) "OLD" DRs (CUSIP # 202597308) for one (1) "NEW" DR (CUSIP# 202597605). Only whole DRs will be distributed.

The following are the trading particulars:

<u>OLD</u> <u>NEW</u> 202597308 202597605

Ticker Symbol: CRZBY CRZBD (reverts back to CRZBY after 20 business days)

Ratio: 1 DS:1 ORDs 1 DS:1 ORDs

BNYM will attempt to sell the fractional DRs and distribute the cash proceeds.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New YorkLondonHong KongRavi DavisDamon RowanJoe OakenfoldVice PresidentVice PresidentVice President+1 212 815-4245+44 207 964 6527+852 2 840 9717

Ravi.davis@bnymellon.com damon.rowan@bnymellon.com joe.oakenfold@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities.